CITIC Eyes $3.65B Takeover Of US-Listed China Biologic
An affiliate of Chinese investment firm Citic Capital offered to buy out U.S.-listed China Biologic in a deal that values the plasma-based biopharmaceutical player at $3.65 billion, after building up a...To view the full article, register now.
Already a subscriber? Click here to view full article